Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas - PubMed (original) (raw)

Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas

Ping Mu et al. Genes Dev. 2009.

Abstract

The miR-17 approximately 92 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA). miR-17 approximately 92 is a direct transcriptional target of c-Myc, and experiments in a mouse model of B-cell lymphomas have shown cooperation between these two oncogenes. However, both the molecular mechanism underlying this cooperation and the individual miRNAs that are responsible for it are unknown. By using a conditional knockout allele of miR-17 approximately 92, we show here that sustained expression of endogenous miR-17 approximately 92 is required to suppress apoptosis in Myc-driven B-cell lymphomas. Furthermore, we show that among the six miRNAs that are encoded by miR-17 approximately 92, miR-19a and miR-19b are absolutely required and largely sufficient to recapitulate the oncogenic properties of the entire cluster. Finally, by combining computational target prediction, gene expression profiling, and an in vitro screening strategy, we identify a subset of miR-19 targets that mediate its prosurvival activity.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

miR-17∼92 suppresses cell death in Eμ-Myc lymphomas. (A) Schematic representation of the miR-17∼92 cluster. Each miRNA is represented by a colored box and is color-coded based on the seed family to which it belongs. The sequence of each mature miRNA is also shown. (B) Schematic of the conditional miR-17∼92 knockout allele. Arrows represent the primers used to detect the floxed and the deleted (Δ) alleles. (C) PCR on genomic DNA extracted from Eμ-Myc;miR-17∼92fl/fl;Cre-ER lymphoma cells mock-treated or after 4 d of 4-OHT treatment. (D) Quantitative RT–PCR analysis of the expression of miR-17∼92 in lymphoma cells before (gray bars) and after (white bars) 4-OHT treatment. Each component of miR-17∼92 was detected independently, and the results were normalized relative to the expression observed in mock-treated cells. Each experiment was performed in quadruplicate. Error bar, standard deviation (SD). (E) Growth curves of _miR-17∼92_fl/fl cells (black line), miR-17∼92Δ/Δ cells (red line), and miR-17∼92Δ/Δ cells infected with a retrovirus expressing the entire miR-17∼92 cluster (blue line). Error bars, SD of three replicates. The plot is representative of three independent experiments. (F) Caspase activity in exponentially growing _miR-17∼92_fl/fl and miR-17∼92Δ/Δ lymphoma cells as detected by flow cytometry using FITC-conjugated VAD-FMK. The percent of VAD-FMK+ cells is shown.

Figure 2.

Figure 2.

miR-19a and miR-19b mediate the prosurvival and oncogenic functions of miR-17∼92 in Eμ-Myc B-cell lymphomas. (A) Schematic of the experimental design. (B) Histogram overlays of miR-17∼92Δ/Δ cells transduced with PIG retroviruses expressing the indicated miR-17∼92 derivatives. The cells were assayed by flow cytometry to detect GFP expression at day 2 (blue plot) and day 8 (red plot) post-infection. A schematic of the miR-17∼92 derivative used is shown below each overlay. (C) Table summarizing the results of the experiments shown in B. (D) Caspase activity in _miR-17∼92_fl/fl and miR-17∼92Δ/Δ cells transduced with the indicated PIG constructs. Error bar, 1 SD deviation. (E) Survival analysis of mice injected with _miR-17∼92_fl/fl and miR-17∼92Δ/Δ lymphoma cells transduced with the indicated PIG constructs. N = 16 mice for each construct, over three independent experiments.

Figure 3.

Figure 3.

Gene expression profiling identifies miR-19 targets in Eμ-Myc lymphoma cells. (A) Description of the various lymphoma cells used. (B) Differences in mRNA levels between _miR-17∼92_fl/fl and miR-17∼92Δ/Δ lymphoma cells transduced with the empty PIG vector were monitored with microarrays. Cumulative distribution function (CDF) plots are shown for mRNAs that do not contain miR-17∼92 seed matches in their 3′UTRs (black line), mRNAs containing one or more seed matches for miR-19 in their 3′UTR (red line), and mRNAs containing one or more seed matches for either miR-17, miR-20a, miR-18a, or miR-92 (blue line). In the absence of endogenous miR-17∼92 expression, a statistically significant up-regulation (_P_-value < 2.22e-16, KS test) is observed for the predicted miR-17∼92 targets relative to the background gene population. (C) CDF plots of the changes in mRNA expression levels between miR-17∼92Δ/Δ + PIG-miR-17∼92 and miR-17∼92Δ/Δ lymphoma cells (left panel) and between miR-17∼92Δ/Δ + PIG-miR-19a,b and miR-17∼92Δ/Δ lymphoma cells (right panel). (D) Venn diagram summarizing the overlap in gene expression changes observed between the various transduction experiments. (E) As in D, but the analysis was restricted to mRNAs whose 3′UTR contains at least one predicted binding site for miR-19.

Figure 4.

Figure 4.

An in vitro RNAi screen to identify functionally relevant miR-19 targets. (A) List of the genes assayed in the in vitro shRNA screen. (B) Scatter plot summarizing the result of the screen. Each dot represents an individual shRNA construct. The _X_-axis is the percentage of GFP cells at the beginning of the experiment (2 d after infection) and the _Y_-axis is the percentage of GFP cells 11 d later. The green dot identifies the empty vector control. shRNAs that scored positive in the screen are highlighted in red and labeled. Dots corresponding to genes for which at least two out of three shRNAs provided significant growth advantage are labeled. PIG-miR-19a/b was included in the screen as positive control (blue dot).

Figure 5.

Figure 5.

Pten is a functionally relevant miR-19 target in B-cell lymphomas. (A) Schematic representation of the Pten 3′UTR with the location of the predicted binding sites for members of the miR-17∼92 cluster and sequence alignments between miR-19b and its two predicted binding sites. (B) Pten Western blot on lysates of B-lymphoma cells transduced with the indicated PIG constructs. (Lanes 8,9) For comparison, lysates from miR-17∼92Δ/Δ cell expressing the two Pten shRNAs that scored positive in the in vitro screen were also assayed. (C) Pten immunohistochemistry on lymphoma sections obtained from mice injected with _miR-17∼92_fl/fl and miR-17∼92Δ/Δ B-lymphoma cells transduced with the indicated miR-17∼92 derivatives (objective, 20×). Brown staining indicates Pten signal. (D) Knockdown of Pten suppresses apoptosis in miR-17∼92Δ/Δ cells. Apoptosis was measured by detecting caspase activity in miR-17∼92fl/fl and miR-17∼92Δ/Δ cells transduced with the indicated retroviruses. (E) Kaplan-Meier survival curve of mice injected with miR-17∼92Δ/Δ lymphoma cells transduced with retroviruses expressing shRNAs against Pten. N = 10 (five mice for shPTEN-1 and five mice for shPTEN-2). For comparison, the survival curves of mice injected with _miR-17∼92_fl/fl, miR-17∼92Δ/Δ, and miR-17∼92Δ/Δ + miR-19a,b from Figure 2C are included.

Comment in

Similar articles

Cited by

References

    1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–538. - PubMed
    1. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455:64–71. - PMC - PubMed
    1. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122:553–563. - PubMed
    1. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136:215–233. - PMC - PubMed
    1. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: Targets and expression. Nucleic Acids Res. 2008;36:D149–D153. doi: 10.1093/nar/gkm995. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources